Clinical Trial Update: Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules [Phase 1]

View source ↗

Summary

This Phase 1 trial evaluates increasing doses and different treatment schedules of the AKT inhibitor AZD5363 (ipatasertib) in patients with advanced solid malig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Or Metastatic Breast Cancer
• Ovarian Cancer
• Solid Malignancies

Drugs mentioned

• AZD5363 (capivasertib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Solid Malignancy, Safety and Tolerability | Phase 1 | Status: COMPLETED